Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Menatetrenone in Postmenopausal Osteoporosis
NCT00548509Phase 4Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2002
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of menatetrenone in osteoporosis (2 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Gamma-carboxylation of osteocalcin at 1 month. Started Feb 2002; status: completed.
02
Drugs
menatetrenone
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00548509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00548509.